Patents by Inventor James A. Monn

James A. Monn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11534434
    Abstract: Provided herein are compounds comprising compounds of formula I and/or salts thereof; wherein at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine, and the remainder are independently chosen from hydrogen and fluorine; and R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 are independently chosen from hydrogen and deuterium; with the proviso that when R1, R2, and R3 are fluorine, then at least one of R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine or at least one of R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 is deuterium. Also provided are medicaments comprising these compounds and methods for treating central nervous system disorders with the compounds and medicaments described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: December 27, 2022
    Assignee: Karuna Therapeutics, Inc.
    Inventors: James A. Monn, Clifford Adam Schlecht, Dennis A. Bennett, Giorgio Attardo
  • Publication number: 20210145810
    Abstract: Provided herein are compounds comprising compounds of formula I and/or salts thereof; wherein at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine, and the remainder are independently chosen from hydrogen and fluorine; and R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 are independently chosen from hydrogen and deuterium; with the proviso that when R1, R2, and R3 are fluorine, then at least one of R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is fluorine or at least one of R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23 is deuterium. Also provided are medicaments comprising these compounds and methods for treating central nervous system disorders with the compounds and medicaments described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 20, 2021
    Inventors: James A. MONN, Clifford Adam SCHLECHT, Dennis A. BENNETT, Giorgio ATTARDO
  • Publication number: 20070265342
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: July 5, 2007
    Publication date: November 15, 2007
    Inventors: David Coffey, James Monn, Concepcion Pedregal-Tercero, Steven Pedersen
  • Publication number: 20050222231
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: June 6, 2003
    Publication date: October 6, 2005
    Applicant: ELI LILLY AND COMPANY
    Inventors: Eric Moher, James Monn, Concepcion Pedregal-Tercero
  • Publication number: 20050009912
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residue R11, R12 and R13 are aas defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: December 5, 2002
    Publication date: January 13, 2005
    Inventors: Ana Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Rafael Ferritto Crespo, Jose Martin, Maria Martinez-Grau, Steven Massey, James Monn, Concepcion Pedregal-Tercero, Matthew Valli, Marc Herin
  • Patent number: 6017957
    Abstract: A method is disclosed for the treatment of neuropsychopharmacological disorders which are associated with or result from excessive activation of the N-methyl-D-aspartate receptor complex, which method comprises administering an effective neuropsychopharmacological disorder-treating amount of a compound possessing partial agonist properties for the strychnine insensitive glycine modulatory sites of N-methyl-D-aspartate receptors. Exemplary of partial agonists which are useful in the method of the invention are 1-aminocyclopropanecarboxylic acid, and associated derivates thereof. Novel injectable pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: August 8, 1989
    Date of Patent: January 25, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Phil Skolnick, Anita Lewin, Juan-Carlos Marvizon, James Monn, Kenner Rice
  • Patent number: 5925782
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: July 20, 1999
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5925680
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: July 20, 1999
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano
  • Patent number: 5750566
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: May 12, 1998
    Assignee: Eli Lilly and Company
    Inventors: James A. Monn, Darryle D. Schoepp
  • Patent number: 5661184
    Abstract: The present invention provides a method of treating substance dependence disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: David R. Helton, Mary Jeanne Kallman, James A. Monn, Darryle D. Schoepp, Joseph P. Tizzano
  • Patent number: 5641798
    Abstract: This invention provides novel bicyclic compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides intermediates useful in the synthesis of excitatory amino acid antagonists.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 24, 1997
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5591867
    Abstract: This invention provides a process for preparing kainic acid and provides intermediates in the synthesis thereof.
    Type: Grant
    Filed: October 30, 1995
    Date of Patent: January 7, 1997
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5552426
    Abstract: This invention provides substituted benzimidazoles which are useful in treating or preventing conditions associated with .beta.-amyloid peptide. Some such conditions associated with .beta.-amyloid peptide include Alzheimer's Disease, Down's Syndrome and amyloidosis of the Dutch type.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: William H. W. Lunn, James A. Monn, Dennis M. Zimmerman
  • Patent number: 5491241
    Abstract: This invention provides novel bicyclic compounds which are useful as excitatory amino acid receptor antagonists and in the treatment of neurological disorders. This invention also provides intermediates useful in the synthesis of excitatory amino acid antagonists.
    Type: Grant
    Filed: October 18, 1993
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5486620
    Abstract: This invention provides a process for preparing kainic acid and provides intermediates in the synthesis thereof.
    Type: Grant
    Filed: April 22, 1994
    Date of Patent: January 23, 1996
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5473077
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: December 5, 1995
    Assignee: Eli Lilly and Company
    Inventors: James A. Monn, Darryle D. Schoepp, Matthew J. Valli
  • Patent number: 5352799
    Abstract: The present invention provides processes for the synthesis of kainic acid. More specifically, the present invention is directed to a process for preparing a compound of the formula ##STR1## wherein R.sub.1 is hydrogen, acyl, alkoxycarbonyl, or arylalkoxycarbonyl;R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, aryl, or arylalkyl; andR.sub.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, aryl, or arylalkyl.The present invention also provides processes for the preparation of intermediates that are useful for the synthesis of kainic acid. More specifically, the present invention provides processes for preparing a compound of the formula ##STR2## wherein R.sub.4 is hydrogen, acyl , alkoxycarbonyl, or arylalkoxycarbonyl; andR.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl, or arylalkyl.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: October 4, 1994
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5319095
    Abstract: This invention provides a process for preparing kainic acid and provides intermediates in the synthesis thereof.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: June 7, 1994
    Assignee: Eli Lilly and Company
    Inventor: James A. Monn
  • Patent number: 5196415
    Abstract: This invention is in the field of clinical neurology and relates specifically to compounds, compositions and methods for treatment of patients with generalized epilepsy or partial (symptomatic) epilepsy using compounds of the formula: ##STR1## This invention also relates to compounds, compositions and methods of treatment for drug craving in patients addicted to cocaine.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: March 23, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: James A. Monn, Andrew Thurkauf, Shunichi Yamaguchi, Michael A. Rogawski, Kenner C. Rice, Mariena V. Mattson, Arthur E. Jacobson